Lv31
372 积分 2025-07-30 加入
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
4小时前
已完结
The Proposed Ninth Edition TNM Classification of Lung Cancer
4小时前
已完结
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
1个月前
已完结
Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis
1个月前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
1个月前
已完结
Safety assessment of antibody-drug conjugates: Nonclinical toxicology, non-active ingredients, and environmental risk considerations
1个月前
已完结
The antibody–drug conjugate landscape
2个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
2个月前
已完结
The Use of Real‐World Evidence for Regulatory Decisions in China
2个月前
已完结
皖公网安备34019202002308
